Company news
Recce Pharmaceuticals Ltd. news in 2024
Recce Pharmaceuticals Ltd.'s news releases, calls and decks from 2024, newest first.
Regulatory Approval for Registrational Phase 3 R327G Trial
December 8, 2024
Australia Patent Granted for RECCE Anti-Infectives
November 25, 2024
AUD $6.75m R&D Rebate Approved
November 13, 2024
Ethics Approval for Registrational Ph3 R327G Clinical Trial
November 10, 2024
AGM Presentation
November 5, 2024
Phase II ABSSSI Clinical Trial Advances to Final Stages
November 4, 2024
Efficacy Data & Approval to Continue Ph II ABSSSI Trial
October 27, 2024
Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway
October 8, 2024
Notice of Special General Meeting/Proxy Form
October 8, 2024
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
August 6, 2024
Successful Completion of Share Purchase Plan
August 4, 2024
Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
July 16, 2024
US Department of Defense Grants US $2m for R327G
July 15, 2024
R327 Efficacy against WHO Priority Pathogen Acinetobacter B
July 8, 2024
Placement & SPP to raise $10 million - Funded to FY26
July 2, 2024
Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
June 27, 2024
Ethics Approval Broadens to All Topical Infections
June 24, 2024
Further R&D Rebate Approved
June 18, 2024
R327 added to WHO List of Antibacterial Products
June 18, 2024
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
June 10, 2024
Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
May 15, 2024
MCRI Pilot Study- Positive Efficacy Data for Lung Infections
May 9, 2024
China Patent Granted for RECCE Anti-Infectives
May 6, 2024
Safety Committee Approves High Dose of 4,000mg
April 26, 2024
Recce Completes 5,000 R327 Doses Per Week under GMP
April 16, 2024
Recce Pharmaceuticals - Business Update
April 7, 2024
Patent Granted in Israel for RECCE Anti-Infectives
April 2, 2024
Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
March 12, 2024
Recce Receives AUD $11.17m R&D Advance
March 7, 2024
Safety Committee Approves Expansion of Ph I/II DFI Trial
February 25, 2024
RCE Establishes Strategic Partnership in South-East Asia
February 5, 2024
Positive Ph I/II DFI Efficacy Data to Support Site Expansion
January 17, 2024
Decks in 2024
- Shareholder Meeting (November 2024)
Shareholder meeting · 18 slides · Nov 6, 2024
- Investor Presentation (March 2024)
Investor deck · 35 slides · March 2024